| US 7,498,336 B2 | ||
| Deazaflavin compounds and methods of use thereof | ||
| Allan M. Weissman, Bethesda, Md. (US); Karen H. Vousden, Glasgow (United Kingdom); Jane P. Jensen, Potomac, Md. (US); Yili Yang, Montgomery Village, Md. (US); Shengyun Fang, Potomac, Md. (US); Douglas Woods, Gaithersburg, Md. (US); John H. Kenten, Boyds, Md. (US); Ilia Davydov, North Potomac, Md. (US); Yassamin J. Safiran, Potomac, Md. (US); and Pankaj Oberoi, Rockville, Md. (US) | ||
| Assigned to The United States of America as represented by the Secretary, Department of Health and Human Services, Washington, D.C. (US); and BioVeris Corporation, Gaithersburg, Md. (US) | ||
| Appl. No. 10/545,547 PCT Filed Feb. 12, 2004, PCT No. PCT/US2004/004130 § 371(c)(1), (2), (4) Date Dec. 09, 2005, PCT Pub. No. WO2004/073615, PCT Pub. Date Sep. 02, 2004. |
||
| Claims priority of provisional application 60/447610, filed on Feb. 13, 2003. | ||
| Prior Publication US 2006/0211718 A1, Sep. 21, 2006 | ||
| Int. Cl. A01N 43/54 (2006.01); A61K 31/505 (2006.01); C07D 239/00 (2006.01); C07D 471/00 (2006.01); C07D 487/00 (2006.01); C07D 491/00 (2006.01) | ||
| U.S. Cl. 514—267 [544/250] | 22 Claims |
1. A method of treating cancer comprising administering to a subject suffering from cancer a compound of the following Formula
IV
 wherein R4 is selected from the group consisting of amino, halogen, hydroxy, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, or mono or di(C1-6alkyl)amino; and pharmaceutically acceptable salts thereof
and wherein the cells of said cancer retain a wild type p53 gene.
|